Compound Edaravone Injection for Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT01929096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 400 participants
- Registry
-
NCT01929096
-
- Other papers using this trial's data
- Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01929096. Randomized; quadruple masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Compound Edaravone Injection for Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Compound Edaravone Injection
- Intervention (Drug)
- Edaravone Injection
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct01929096- Content hash
9ab31c966a9fea1d6d39bd2808816d63ec0b54fa11dca3f60760a39e81dc1900